EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis

Zixuan Li, Juan Zhang, Yaqi Zheng, Mingyan Zhang, Wenkang Du, Yajun Zhang, Xiaochao Gao, Qing Zhu, Jinxu Qi, Zuotao Zhao, Lijuan Liu

Frontiers in Medicine · 13.08.2026 · 13

DOI: 10.3389/fmed.2026.1880701 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Medicine, online erschienen am 13.08.2026. Verfasst von Zixuan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis.

Methods

Seven electronic databases were searched, including PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and Chinese Biomedical Literature Service System. Relevant literature from inception to the end of December 2025 was retrieved. Studies meeting the criteria were selected, and network meta-analysis was performed using Stata 16 software.

Results

A total of 54 studies involving 7,290 patients were included. Network meta-analysis indicated that olopatadine, mizolastine, bilastine, and levocetirizine were more effective than placebo in improving total symptom scores. All 10 drugs were superior to placebo in reducing itching scores, although only fexofenadine achieved statistical significance. For reducing wheal scores, ebastine was significantly more effective than mizolastine and loratadine. Regarding adverse reactions, no significant differences were observed between any of the drugs and placebo, with fexofenadine having the lowest adverse reaction rate. Sensitivity analyses excluding highrisk studies confirmed the robustness of findings across all outcomes.

Conclusion

Based on current evidence, olopatadine at licensed dose exhibited the best efficacy in reducing total symptom scores. Fexofenadine was most effective for improving itching scores and ebastine was optimal for reducing wheal scores. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials.

Schlagwörter

Stichwörter der Autor:innen

antihistamineschronic spontaneous urticariachronic urticarialicensed dosenetwork meta-analysissecond-generation H1 antihistaminestreatment comparison

Autor:innen und Institutionen

  • Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang, Hebei, China.
  • Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang, Hebei, China.
  • Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Hebei Province Key Laboratory of Environment and Human Health, Shijiazhuang, China.
  • Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
  • Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin Institute of Integrative Dermatology, Tianjin, China.

Zitieren

APA

Li, Z., Zhang, J., Zheng, Y., Zhang, M., Du, W., Zhang, Y., Gao, X., Zhu, Q., Qi, J., Zhao, Z., & Liu, L. (2026). Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1880701

Vancouver

Li Z, Zhang J, Zheng Y, Zhang M, Du W, Zhang Y, et al. Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1880701

BibTeX
@article{Li2026,
  author = {Li, Zixuan and Zhang, Juan and Zheng, Yaqi and Zhang, Mingyan and Du, Wenkang and Zhang, Yajun and Gao, Xiaochao and Zhu, Qing and Qi, Jinxu and Zhao, Zuotao and Liu, Lijuan},
  title = {Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1880701}
}
Kostenlos starten →